Acta Med. 2007, 50: 207-212

https://doi.org/10.14712/18059694.2017.84

Phenotype Analysis of Tumour-infiltrating Lymphocytes and Lymphocytes in Peripheral Blood in Patients with Renal Carcinoma

Otakar Kopeckýa,b, Šárka Lukešováa,b, Vladimíra Vroblovác, Doris Vokurkovác, Petr Morávekd, Hynek Šafránekd, Dagmar Hlávkovác, Petr Součekc

aCharles University in Prague, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Oncological Department of District Hospital, Náchod, Czech Republic
bCharles University in Prague, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, 2nd Department of Internal Medicine, Division of Haematology, Hradec Králové, Czech Republic
cCharles University in Prague, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Department of Clinical Immunology and Allergology, Hradec Králové, Czech Republic
dCharles University in Prague, Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové, Department of Urology, Hradec Králové, Czech Republic

Received September 1, 2006
Accepted July 1, 2007

Crossref Cited-by Linking

  • Alkhouli Mohammed A., Bazargan Sarah, Pilon-Thomas Shari, Poch Michael, Chahoud Jad: Current State of Cell Therapies for Genitourinary Malignancies. Cancer J 2022, 28, 294. <https://doi.org/10.1097/PPO.0000000000000604>
  • Feng Tao, Zhao Jiahui, Wei Dechao, Guo Pengju, Yang Xiaobing, Li Qiankun, Fang Zhou, Wei Ziheng, Li Mingchuan, Jiang Yongguang, Luo Yong: Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer. Front. Immunol. 2021, 12. <https://doi.org/10.3389/fimmu.2021.762120>
  • Kim Hyunho, Shim Byoung Yong, Lee Seung-Ju, Lee Ji Youl, Lee Hyo-Jin, Kim In-Ho: Loss of Von Hippel–Lindau (VHL) Tumor Suppressor Gene Function: VHL–HIF Pathway and Advances in Treatments for Metastatic Renal Cell Carcinoma (RCC). IJMS 2021, 22, 9795. <https://doi.org/10.3390/ijms22189795>
  • Volkova M. I., Olshanskaya A. S., Khochenkov D. A., Ashuba S. A., Khochenkova Yu. A., Tsimafeyeu I. V.: Expression of Receptor Tyrosine Kinases on Peripheral Blood Lymphocyte Subpopulations in Patients with Renal Cell Carcinoma and Healthy Volunteers. Malignant Tumours 2020, 9, 18. <https://doi.org/10.18027/2224-5057-2019-9-4-18-24>
  • Kobayashi Yukari, Yamada Daisuke, Kawai Taketo, Sato Yusuke, Teshima Taro, Yamada Yuta, Nakamura Masaaki, Suzuki Motofumi, Matsumoto Akihiko, Nakagawa Tohru, Hosoi Akihiro, Nagaoka Koji, Karasaki Takahiro, Matsushita Hirokazu, Kume Haruki, Kakimi Kazuhiro: Different immunological effects of the molecular targeted agents sunitinib, everolimus and temsirolimus in patients with renal cell carcinoma. Int J Oncol 2020. <https://doi.org/10.3892/ijo.2020.4975>
  • Yu Nengwang, Fu Shuai, Xu Zhonghua, Liu Yi, Hao Junwen, Zhang Aimin, Wang Baocheng: Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma. Int. J. Cancer 2016, 138, 451. <https://doi.org/10.1002/ijc.29713>
  • Chehval Vincent, Norian Lyse A.: Effects of obesity on immune responses to renal tumors. Immunol Res 2014, 59, 211. <https://doi.org/10.1007/s12026-014-8533-0>
  • Chaves K C B, Peron J P S, Chammas R, Turaça L T, Pesquero J B, Braga M S, Foguer K, Schor N, Bellini M H: Endostatin gene therapy stimulates upregulation of ICAM-1 and VCAM-1 in a metastatic renal cell carcinoma model. Cancer Gene Ther 2012, 19, 558. <https://doi.org/10.1038/cgt.2012.32>
  • Geiger Christiane, Nößner Elfriede, Frankenberger Bernhard, Falk Christine S., Pohla Heike, Schendel Dolores J.: Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma. J Mol Med 2009, 87, 595. <https://doi.org/10.1007/s00109-009-0455-2>
Crossref Cited-by Linking logo